A collaboration between the Drakesmith and Higgs Groups at the MRC Weatherall Institute of Molecular Medicine has identified an ancient connection between metabolic and transcriptional control of erythropoiesis.
Associate Professor Adam Wilkinson has received the 2025 Janet Rowley Award from the International Society for Experimental Haematology for his outstanding contributions in the field of hematopoietic stem cell biology.
For International Women's Day on 8th March 2025, women from the MRC WIMM reflect on why this day is so important, the barriers and biases women can face in their careers, and which women have inspired them.
The Therapy Acceleration Lab (TAL) at the MRC WIMM was recently accredited by the United Kingdom Accreditation Service (UKAS) to the ISO 17025:2017 Standard as a testing laboratory, No. 28562.
Alison Kay and Anne Goriely, together with Minna Jeffery (St. Anne\u2019s College) and Lisa Hinton (Nuffield Dept. of Primary Care Health Sciences), have won an award from the University of Oxford\u2019s PCER Fund for a project called \u201cMaking it personal\u201d, which will use theatre to explore public perception of a new form of genetic testing.
Professor Simon Davis and Dr Mafalda Santos have won a 5-year award from the global charitable foundation Wellcome to fund a project titled \u201cSmall contacts, big decisions \u2013 early signal processing by T cells\u201d. This has been awarded jointly with Professor Anna Lippert of the University of W\u00fcrzburg.
Researchers from RDM\u2019s Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) and the MRC Weatherall Institute of Molecular Medicine (WIMM) took centre stage at this year's IF Oxford Science and Ideas Festival with some exciting and interactive public engagement activities.
In 1989, Sir David Weatherall founded the Institute of Molecular Medicine to bridge the gap between basic science and clinical medicine. To mark 35 years since the MRC WIMM opened its labs, we're looking back on some of our highlights and achievements.
Research from the MRC Molecular Haematology Unit has revealed a protein called galectin-1 as a key marker for disease progression and as a promising therapeutic target for patients with myeloproliferative neoplasms (a type of blood cancer).
In a study published in the Journal of Clinical Oncology, an international research team has used machine learning to improve risk stratification for patients over 60 diagnosed with acute myeloid leukaemia, an aggressive type of blood cancer.
Researchers from the MRC Weatherall Institute of Molecular Medicine (WIMM) have shown that blood stem cell subtypes found in mice also exist in humans. This provides important information for research into therapies to alleviate the negative effects of aging.
Yellowstone Biosciences, a biotechnology spinout, has launched to pioneer new cancer treatments using advanced T-cell therapies based on groundbreaking research from the MRC Weatherall Institute of Molecular Medicine at the University of Oxford.
Researchers from the Simmons and Koohy Groups in the Weatherall Institute of Molecular Medicine (WIMM) Translational Immune Discovery Unit have identified potential pathways by which cancer treatment can cause colitis.
![\"Abstract](\"https://www.rdm.ox.ac.uk/news/ancient-link-rbc-synthesis/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n